USC study tests if mindfulness boosts psilocybin's antidepressant effects

USC study tests if mindfulness boosts psilocybin's antidepressant effects

USC Researchers Secure Funding to Initiate First Clinical Study of Psilocybin for Mental Health

USC study tests if mindfulness boosts psilocybin's antidepressant effects

A new clinical study at the University of Southern California is exploring psychedelic therapy using psilocybin. The research aims to assess whether mindfulness meditation can boost the treatment’s benefits for depression. The FDA has already recognised psilocybin as a breakthrough therapy for major depressive disorder and treatment-resistant cases. The investigation involves around 72 middle-aged adults from the Los Angeles area. Participants are split into two groups: one receiving psilocybin alone, the other combining it with mindfulness meditation training. Dr Rael Cahn and Dr Caryn Lerman, specialists in mindfulness science and psychiatry, are co-leading the project.

Before and after the intervention, researchers will conduct extensive assessments. These include EEG, MRI/fMRI scans, biological sampling, and psychological tests. The study uses an open-label design, ensuring full transparency, and employs advanced neuroimaging and biological assays.

Follow-up evaluations at three, six, and twelve months will track the lasting effects of the treatment. Psilocybin is known to alter sensory processing, time perception, and self-awareness, often leading to deep spiritual experiences. The research is funded by a grant from ARPA-H under its EVIDENT initiative. The study seeks to determine if mindfulness can enhance psilocybin’s therapeutic impact. Results could provide new insights into rapid-acting treatments for depression. The findings will be closely monitored over the coming year.

Neueste Nachrichten